PC
Basic information
Region (hg38): 11:66848417-66958386
Links
Phenotypes
GenCC
Source:
- pyruvate carboxylase deficiency disease (Definitive), mode of inheritance: AR
- pyruvate carboxylase deficiency disease (Definitive), mode of inheritance: AR
- pyruvate carboxylase deficiency, infantile form (Supportive), mode of inheritance: AR
- pyruvate carboxylase deficiency, severe neonatal type (Supportive), mode of inheritance: AR
- pyruvate carboxylase deficiency, benign type (Supportive), mode of inheritance: AR
- pyruvate carboxylase deficiency disease (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pyruvate carboxylase deficiency | AR | Biochemical | In acute episodes, acidosis correction and glucose-containing rehydration are beneficial; Dietary (eg, with high-carbohydrate, low-protein diet, with avoidance of fasting/ketogenic diet) and medical (eg, with supplementation/substrate therapy with citrate, aspartic acid, biotin, triheptanoin) therapy may be beneficial; Liver transplant may be required in some individuals | Biochemical; Neurologic | 5771860; 817914; 826106; 6422151; 6424438; 3101494; 1909777; 9585612; 12112657; 16325442; 17403843; 18676167; 19306334; 20301764; 37207470 |
ClinVar
This is a list of variants' phenotypes submitted to
- Pyruvate carboxylase deficiency (57 variants)
- Global developmental delay (1 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PC gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 543 | 553 | ||||
missense | 191 | 40 | 245 | |||
nonsense | 13 | 16 | 29 | |||
start loss | 0 | |||||
frameshift | 33 | 50 | 83 | |||
inframe indel | 10 | |||||
splice donor/acceptor (+/-2bp) | 18 | 26 | ||||
splice region | 10 | 78 | 4 | 92 | ||
non coding | 53 | 237 | 301 | |||
Total | 59 | 95 | 255 | 820 | 18 |
Highest pathogenic variant AF is 0.0000263
Variants in PC
This is a list of pathogenic ClinVar variants found in the PC region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-66848526-G-A | Pyruvate carboxylase deficiency | Uncertain significance (Jun 14, 2016) | ||
11-66848546-T-C | Pyruvate carboxylase deficiency | Uncertain significance (Jan 12, 2018) | ||
11-66848696-A-G | Pyruvate carboxylase deficiency | Uncertain significance (Jan 13, 2018) | ||
11-66848711-C-T | Pyruvate carboxylase deficiency | Uncertain significance (Jan 13, 2018) | ||
11-66848714-C-T | Pyruvate carboxylase deficiency | Uncertain significance (Jan 12, 2018) | ||
11-66848734-G-GA | Pyruvate carboxylase deficiency | Uncertain significance (Jun 14, 2016) | ||
11-66848738-G-A | Pyruvate carboxylase deficiency | Uncertain significance (Jan 12, 2018) | ||
11-66848793-C-A | Pyruvate carboxylase deficiency | Benign (Jan 13, 2018) | ||
11-66848798-C-T | Pyruvate carboxylase deficiency | Uncertain significance (Jan 12, 2018) | ||
11-66848810-C-T | Pyruvate carboxylase deficiency | Conflicting classifications of pathogenicity (Jun 10, 2019) | ||
11-66848811-C-T | Pyruvate carboxylase deficiency | Uncertain significance (Jan 13, 2018) | ||
11-66848856-G-A | Pyruvate carboxylase deficiency | Uncertain significance (Jan 12, 2018) | ||
11-66848884-C-T | Pyruvate carboxylase deficiency • not specified | Conflicting classifications of pathogenicity (Jan 12, 2018) | ||
11-66848886-G-A | PC-related disorder | Benign (Mar 03, 2015) | ||
11-66848905-G-A | Pyruvate carboxylase deficiency | Conflicting classifications of pathogenicity (Jan 31, 2024) | ||
11-66848905-G-T | Pyruvate carboxylase deficiency | Likely benign (Sep 09, 2023) | ||
11-66848908-C-T | Pyruvate carboxylase deficiency | Likely benign (Mar 26, 2022) | ||
11-66848910-C-T | Pyruvate carboxylase deficiency | Uncertain significance (Aug 30, 2023) | ||
11-66848914-G-A | Pyruvate carboxylase deficiency | Likely benign (Feb 20, 2023) | ||
11-66848916-T-G | not specified | Uncertain significance (Aug 19, 2015) | ||
11-66848917-G-A | Pyruvate carboxylase deficiency | Likely benign (Sep 12, 2022) | ||
11-66848922-C-A | Pyruvate carboxylase deficiency | Uncertain significance (Feb 27, 2022) | ||
11-66848922-C-T | Pyruvate carboxylase deficiency | Conflicting classifications of pathogenicity (Jan 08, 2024) | ||
11-66848923-G-A | Pyruvate carboxylase deficiency • PC-related disorder | Likely benign (Feb 01, 2024) | ||
11-66848932-C-T | Pyruvate carboxylase deficiency | Likely benign (Jun 30, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PC | protein_coding | protein_coding | ENST00000393960 | 20 | 110144 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0138 | 0.986 | 125712 | 0 | 34 | 125746 | 0.000135 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.06 | 516 | 752 | 0.686 | 0.0000525 | 7619 |
Missense in Polyphen | 171 | 320.53 | 0.53349 | 3198 | ||
Synonymous | -1.39 | 359 | 327 | 1.10 | 0.0000244 | 2463 |
Loss of Function | 4.64 | 13 | 47.5 | 0.274 | 0.00000267 | 531 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000304 | 0.000304 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.000290 | 0.000277 |
European (Non-Finnish) | 0.000133 | 0.000132 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Pyruvate carboxylase catalyzes a 2-step reaction, involving the ATP-dependent carboxylation of the covalently attached biotin in the first step and the transfer of the carboxyl group to pyruvate in the second. Catalyzes in a tissue specific manner, the initial reactions of glucose (liver, kidney) and lipid (adipose tissue, liver, brain) synthesis from pyruvate.;
- Disease
- DISEASE: Pyruvate carboxylase deficiency (PC deficiency) [MIM:266150]: Leads to lactic acidosis, mental retardation and death. It occurs in three forms: mild or type A, severe neonatal or type B, and a very mild lacticacidemia. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Citrate cycle (TCA cycle) - Homo sapiens (human);Pyruvate metabolism - Homo sapiens (human);Warburg Effect;Pyruvate Dehydrogenase Complex Deficiency;Pyruvate Carboxylase Deficiency;Primary Hyperoxaluria Type I;Lactic Acidemia;Transfer of Acetyl Groups into Mitochondria;The oncogenic action of Succinate;The oncogenic action of Fumarate;Primary hyperoxaluria II, PH2;Pyruvate kinase deficiency;Pyruvate dehydrogenase deficiency (E3);Pyruvate dehydrogenase deficiency (E2);2-ketoglutarate dehydrogenase complex deficiency;Mitochondrial complex II deficiency;Fumarase deficiency;Congenital lactic acidosis;Gluconeogenesis;Citric Acid Cycle;Alanine Metabolism;Leigh Syndrome;Glycogenosis, Type IA. Von gierke disease;Glycogenosis, Type IC;Glutaminolysis and Cancer;The oncogenic action of 2-hydroxyglutarate;Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease;Pyruvate Metabolism;The oncogenic action of L-2-hydroxyglutarate in Hydroxygluaricaciduria;The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria ;Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency);Triosephosphate isomerase;Fructose-1,6-diphosphatase deficiency;Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1);Glycogenosis, Type IB;Alanine and aspartate metabolism;TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc);Fatty Acid Biosynthesis;Amino Acid metabolism;Glycolysis and Gluconeogenesis;Biotin transport and metabolism;Metabolism of carbohydrates;Citrate cycle;Alanine Aspartate Asparagine metabolism;Glycolysis Gluconeogenesis;Glycolysis and Gluconeogenesis;Metabolism;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors;gluconeogenesis;Gluconeogenesis;Glucose metabolism
(Consensus)
Recessive Scores
- pRec
- 0.818
Intolerance Scores
- loftool
- 0.00882
- rvis_EVS
- -1.74
- rvis_percentile_EVS
- 2.39
Haploinsufficiency Scores
- pHI
- 0.194
- hipred
- Y
- hipred_score
- 0.694
- ghis
- 0.508
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.974
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pcx
- Phenotype
- growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Zebrafish Information Network
- Gene name
- pcxa
- Affected structure
- habituation
- Phenotype tag
- abnormal
- Phenotype quality
- decreased process quality
Gene ontology
- Biological process
- pyruvate metabolic process;gluconeogenesis;lipid metabolic process;biotin metabolic process;negative regulation of gene expression;viral RNA genome packaging;positive regulation by host of viral release from host cell;positive regulation by host of viral process
- Cellular component
- cytoplasm;mitochondrion;mitochondrial matrix;cytosol
- Molecular function
- pyruvate carboxylase activity;protein binding;ATP binding;biotin binding;identical protein binding;metal ion binding